iCAD Reports Second Quarter 2018 Financial Results
PowerLook Tomo Detection Version 2.0 Submitted for FDA Approval
Conference call today at 4:30 p.m. ET
NASHUA, N.H. (August 14, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology
company providing innovative cancer detection and therapy solutions, today reported financial results for the three and six months ended June 30, 2018.
Second Quarter 2018 Highlights:
- Total revenue of $6.2 million, down 4% year-over-year
- Gross profit of $4.8 million, or 78%
- GAAP Net Loss of ($1.0) million, or ($0.06) per share
- Non-GAAP Adjusted EBITDA loss of ($0.3) million
- Submitted PowerLook Tomo Detection Version 2.0 for FDA approval in May